NCT05453825View on ClinicalTrials.gov

A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

PHASE2UnknownINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

August 5, 2022

Primary Completion Date

April 15, 2024

Study Completion Date

December 15, 2024

Conditions
Colorectal CancerTriple Negative Breast CancerGastric CancerOvarian Cancer
Interventions
BIOLOGICAL

navicixizumab+paclitaxel

navicixizumab 3 mg/kg Q2W; paclitaxel 80 mg/m2 weekly

BIOLOGICAL

navicixizumab+irinotecan

navicixizumab 3 mg/kg Q2W; irinotecan 180 mg/m2 Q2W

BIOLOGICAL

navicixizumab monotherapy

navicixizumab 3 mg/kg Q2W

Trial Locations (8)

10016

RECRUITING

New York University - Langone Health - Perlmutter Cancer Center, New York

30322

RECRUITING

Northside Hospital, Atlanta

33612

RECRUITING

Moffitt Cancer Center, Tampa

37203

RECRUITING

Tennessee Oncology, Nashville

43219

RECRUITING

The Zangmeister Cancer Center, Columbus

70809

RECRUITING

Hematology Oncology Clinic, Baton Rouge

71913

RECRUITING

Genesis Cancer Center, Hot Springs

90033

RECRUITING

Keck Medicine of USC, Los Angeles

Sponsors
All Listed Sponsors
lead

OncXerna Theraputics, Inc.

INDUSTRY